Shared insight from expert oncologists on key clinical trial data in lymphomas from the ASCO 2022 and EHA 2022 Annual Meetings.
Kieron Dunleavy, MD
Advertisement
Articles by Kieron Dunleavy, MD
Expert oncologist perspectives on key clinical trial data in acute lymphocytic leukemia from the ASCO 2022 and EHA 2022 Annual Meetings.
Dr. Kieron Dunleavy, from the National Cancer Institute, Discusses Treatment Options for Primary Mediastinal B Cell Lymphoma
Dr. Kieron Dunleavy, from the National Cancer Institute, Discusses ABC DLBCL Research
Dr. Kieron Dunleavy from the National Cancer Institute Discusses 3 Molecular Subtypes of DLBCL
Advertisement
Latest Updated Articles
Lymphomas Trial Data From the ASCO 2022 and EHA 2022 Annual MeetingsPublished: July 13th 2022 | Updated:
Acute Lymphocytic Leukemia Trial Data From the ASCO 2022 and EHA 2022 Annual MeetingsPublished: July 13th 2022 | Updated:
Dr. Dunleavy Discusses ABC DLBCL ResearchPublished: March 23rd 2012 | Updated:
Dr. Dunleavy Discusses Treatment Options for PMBLPublished: April 16th 2012 | Updated:
Dr. Dunleavy Discusses 3 Molecular Subtypes of DLBCLPublished: February 24th 2012 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
4
Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma
5